Abstract
Insufficient evidence exists to determine which specific combinations most effectively decrease cardiovascular morbidity and mortality, although combinations of hypertension medications at lower doses generally reduce cardiovascular outcomes (stroke, coronary heart disease) more than monotherapy (strength of recommendation [SOR]: A, large meta-analyses).The combination of benazepril and amlodipine reduces the composite endpoint of cardiovascular events and deaths more than benazepril plus hydrochlorothiazide with similar rates of adverse effects (SOR: A, randomized controlled trial [RCT]).Combining an angiotensin converting enzyme inhibitor (ACE-I) with a thiazide, ß-blocker, or calcium channel blocker produces side effects similar to monotherapy, as does combining an angiotensin receptor blocker (ARB) with a thiazide or calcium channel blocker (SOR: A, meta-analyses). However, an ACE-I combined with an ARB increases the risk of renal complications and death more than monotherapy (SOR: A, RCT)..
Original language | English |
---|---|
Pages (from-to) | 684-6 |
Number of pages | 3 |
Journal | Journal of Family Practice |
Volume | 60 |
Issue number | 11 |
State | Published - Nov 2011 |
Externally published | Yes |
Keywords
- Angiotensin Receptor Antagonists/therapeutic use
- Angiotensin-Converting Enzyme Inhibitors/therapeutic use
- Antihypertensive Agents/therapeutic use
- Calcium Channel Blockers/therapeutic use
- Drug Therapy, Combination
- Humans
- Hypertension/drug therapy
- Practice Guidelines as Topic
- Thiazides/therapeutic use